HRP980378B1 - Encapsulated solution dosage forms of sertraline - Google Patents

Encapsulated solution dosage forms of sertraline

Info

Publication number
HRP980378B1
HRP980378B1 HR980378A HRP980378A HRP980378B1 HR P980378 B1 HRP980378 B1 HR P980378B1 HR 980378 A HR980378 A HR 980378A HR P980378 A HRP980378 A HR P980378A HR P980378 B1 HRP980378 B1 HR P980378B1
Authority
HR
Croatia
Prior art keywords
sertraline
dosage forms
solution dosage
encapsulated solution
encapsulated
Prior art date
Application number
HR980378A
Other languages
English (en)
Inventor
William John Curatolo
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980378(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP980378A2 publication Critical patent/HRP980378A2/hr
Publication of HRP980378B1 publication Critical patent/HRP980378B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HR980378A 1997-07-01 1998-07-01 Encapsulated solution dosage forms of sertraline HRP980378B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5140197P 1997-07-01 1997-07-01

Publications (2)

Publication Number Publication Date
HRP980378A2 HRP980378A2 (en) 1999-04-30
HRP980378B1 true HRP980378B1 (en) 2001-12-31

Family

ID=21971076

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980378A HRP980378B1 (en) 1997-07-01 1998-07-01 Encapsulated solution dosage forms of sertraline

Country Status (40)

Country Link
EP (1) EP0980241B1 (fr)
JP (1) JP3585245B2 (fr)
KR (1) KR100371730B1 (fr)
CN (1) CN1261792A (fr)
AP (1) AP945A (fr)
AR (1) AR015916A1 (fr)
AT (1) ATE256457T1 (fr)
AU (1) AU724635B2 (fr)
BG (1) BG103917A (fr)
BR (1) BR9809712A (fr)
CA (1) CA2290973C (fr)
CO (1) CO4940405A1 (fr)
DE (1) DE69820608T2 (fr)
DK (1) DK0980241T3 (fr)
DZ (1) DZ2544A1 (fr)
EA (1) EA001905B1 (fr)
ES (1) ES2210760T3 (fr)
GT (1) GT199800090A (fr)
HR (1) HRP980378B1 (fr)
HU (1) HUP0002250A3 (fr)
ID (1) ID24673A (fr)
IL (1) IL133075A0 (fr)
IS (1) IS5266A (fr)
MA (1) MA24586A1 (fr)
MY (1) MY119728A (fr)
NO (1) NO996492L (fr)
NZ (1) NZ501252A (fr)
OA (1) OA11246A (fr)
PA (1) PA8454001A1 (fr)
PE (1) PE97299A1 (fr)
PL (1) PL337807A1 (fr)
PT (1) PT980241E (fr)
SK (1) SK282914B6 (fr)
TN (1) TNSN98123A1 (fr)
TR (1) TR199903282T2 (fr)
TW (1) TW382597B (fr)
UA (1) UA68350C2 (fr)
UY (1) UY25070A1 (fr)
WO (1) WO1999001113A1 (fr)
ZA (1) ZA985709B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
EE04868B1 (et) * 1998-10-13 2007-08-15 Pfizer Products Inc. Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis
UA75580C2 (uk) 1999-09-03 2006-05-15 Апбі Холдінгс, Ллк Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
CA2420535A1 (fr) 2000-08-30 2002-03-07 Mary Tanya Am Ende Formulations a liberation prolongee pour les secretagogues de l'hormone de croissance
EP1375659A1 (fr) * 2002-06-18 2004-01-02 Laboratorio di Diagnostica Moleculare Mélanges concentrés dans des capsules solubles pour la préparation facilitée de solutions chimiques ou biologiques
US20040142040A1 (en) * 2002-10-31 2004-07-22 Dong Liang C. Formulation and dosage form providing increased bioavailability of hydrophobic drugs
WO2016020936A2 (fr) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal Nouvelle forme posologique pharmaceutique orale de rétention gastrique
CN108014087A (zh) * 2017-12-27 2018-05-11 江苏联环药业股份有限公司 一种盐酸舍曲林胶囊的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2197554A1 (fr) * 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combinaison d'un antagoniste opioide et d'un inhibiteur de la reabsortion selective de serotonine pour le traitement de l'alcoolisme et de la dependance de l'alcool
DK0768083T3 (da) * 1995-07-17 2003-06-23 Pfizer Anvendelse af sertralin til at behandle patienter med post myocardisk infarkt

Also Published As

Publication number Publication date
OA11246A (en) 2002-11-19
ID24673A (id) 2000-07-27
DE69820608D1 (de) 2004-01-29
EA199900963A1 (ru) 2000-08-28
PT980241E (pt) 2004-03-31
CA2290973C (fr) 2003-06-17
JP2000512316A (ja) 2000-09-19
TNSN98123A1 (fr) 2005-03-15
NZ501252A (en) 2004-11-26
CO4940405A1 (es) 2000-07-24
EP0980241B1 (fr) 2003-12-17
HUP0002250A3 (en) 2001-01-29
JP3585245B2 (ja) 2004-11-04
CN1261792A (zh) 2000-08-02
HUP0002250A2 (hu) 2000-12-28
HRP980378A2 (en) 1999-04-30
TR199903282T2 (xx) 2000-08-21
EA001905B1 (ru) 2001-10-22
BG103917A (bg) 2000-07-31
KR100371730B1 (ko) 2003-02-07
SK282914B6 (sk) 2003-01-09
ZA985709B (en) 2000-01-10
AU7545098A (en) 1999-01-25
NO996492L (no) 2000-02-29
TW382597B (en) 2000-02-21
WO1999001113A1 (fr) 1999-01-14
MA24586A1 (fr) 1998-12-31
IS5266A (is) 1999-11-23
DE69820608T2 (de) 2004-12-23
KR20010013588A (fr) 2001-02-26
EP0980241A1 (fr) 2000-02-23
UA68350C2 (en) 2004-08-16
CA2290973A1 (fr) 1999-01-14
PA8454001A1 (es) 2000-05-24
AR015916A1 (es) 2001-05-30
DZ2544A1 (fr) 2003-02-08
DK0980241T3 (da) 2004-04-05
SK180599A3 (en) 2001-01-18
BR9809712A (pt) 2000-07-11
PL337807A1 (en) 2000-09-11
AP945A (en) 2001-02-28
AP9801279A0 (en) 1998-06-30
ATE256457T1 (de) 2004-01-15
PE97299A1 (es) 1999-10-13
ES2210760T3 (es) 2004-07-01
UY25070A1 (es) 2000-12-29
AU724635B2 (en) 2000-09-28
NO996492D0 (no) 1999-12-27
MY119728A (en) 2005-07-29
IL133075A0 (en) 2001-03-19
GT199800090A (es) 1999-12-21

Similar Documents

Publication Publication Date Title
HUP0002296A3 (en) Sertraline salts and sustained-release dosage forms of sertraline
HUP0000759A3 (en) Dosage forms comprising separate portions of r- and s-enantiomers
SI0948541T1 (sl) PTHrP analogi
IL119890A0 (en) Preparation of gabapentin
HK1027982A1 (en) Delayed-release dosage forms of sertraline
HUP0003518A3 (en) Treatment of formaldehyde-containing mixtures
AP9801279A0 (en) Encapsulated solution dosage forms of sertraline
GB2326116B (en) Treatment of chocolate
PL338781A1 (en) Dosage form
EP0981545A4 (fr) Traitement de l'osteoporose
SI0980241T1 (en) Gelatine encapsulated solution dosage forms of sertraline
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
IL120955A0 (en) Treatment of osteoporosis
GB2329384B (en) Preparation of 1-chloro-1-cyclopropylethene
IL123105A0 (en) Preparation of brominated indanes
ZA985707B (en) Sertraline salts and sustained-release dosage forms of sertraline.
GB9718683D0 (en) Novel dosage form
GB9704978D0 (en) Dosage forms
GB9719261D0 (en) Dosage forms
GB9703750D0 (en) Treatment of haemorrhoids
HU9701917D0 (en) New compound of medicinal activity
TW339575U (en) Improved structure of shoes
TW322782U (en) Structure improvement of walker
TW357561U (en) Improvement of shoe structure
GB9707576D0 (en) Enhancement of oral hygiene

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040614

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20050702